Substituted azetidin-2-ones for treatment of atherosclerosis
US5990102A · kind A · utility
16Cited by
0References
21Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 21, 1997 |
| Grant date | Nov 23, 1999 |
| Priority date | — |
| Expiry date | Nov 21, 2017 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compounds of formula (I) in which R.sup.1 and R.sup.2, which may be the same or different, is each selected from hydrogen, halogen or C.sub.(1-8) alkyl; R.sup.3 is aryl or aryl C.sub.(1-4) alkyl which may be optionally substituted; X is a linker group; Y is an optionally substituted aryl group; and n is 0, 1 or 2; are inhibitors of the enzyme Lp-PLA.sub.2 and thereof of use in treating atherosclerosis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.